Det er jo tydeligvis flere innen farmasi som vil ha samarbeid med PCIB, så det kan vel ikke være så elendig?

Egentlig ikke så underlig at samarbeidsavtaler kun fører til et lite kursblaff akkurat når de blir meldt i dette caset, historikken er ikke på Pcib sin side. Her gjelder "sell on news". At Pcib sannsynligvis aldri greier å få til noe er helt greit, men de bør klare å skape såpass forventninger at kursen får en opptur.

Underlig at de siste meldingene ikke skal ha noe positiv effekt på PCIB?

Meget offensive toner fra CEO hos Olix P.:
"We are very excited to collaborate with PCI Biotech. Combining our proprietary
asiRNA platform with PCI's leading fimaNAc delivery technology will
significantly accelerate our efforts to bring our dermatological RNAi programs
to the clinic. We also expect to expand the area of application to our cancer
immunotherapy pipeline and mRNA vaccines developed by our subsidiary, mCureX, in
the near future."

Her tenker man et utvidet samarbeid innen mRNA som også vil omfatte vaksiner og kreftlegemidler.

PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
Oslo (Norway), 26 October 2020 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today announced that the first Asian patient in
the fimaChem pivotal RELEASE study with registration intent in inoperable bile
duct cancer patients has been enrolled in South Korea. The RELEASE study spans
across Europe, USA and Asia, following the recent opening of several clinical
sites in both South Korea and Taiwan.

PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology
?Oslo (Norway), 23 November 2020 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announced that the results from the successful
Phase I proof of concept study for the fimaVacc technology is accepted for
publication in Frontiers in Immunology, a high impact immunology journal. The
article title is "Photochemical internalization enhanced vaccination is safe,
and gives promising cellular immune responses to an HPV peptide-based vaccine in
a phase I clinical study in healthy volunteers" and the abstract of the
publication is available through this link:
https://www.frontiersin.org/articles/10.3389/fimmu.2020.576756/abstract.

Lovende det som skjer nå.
OliX Pharmaceuticals and PCI Biotech announce a collaboration to combine OliX asiRNA and PCI Biotech fimaNAc technologies
Suwon, South Korea and Oslo, Norway, May, 5(t)(h) 2021 - OliX Pharmaceuticals
Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech
(OSE: PCIB), a cancer focused biopharmaceutical company with a unique
intracellular delivery technology, today announced an extensive research
collaboration. OliX Pharmaceuticals and PCI Biotech will combine their know-how
and technology platforms to explore synergies and further partnership on
dermatology and other applications.

The partnership is governed by a research collaboration agreement, under which
the collaborators will perform an extensive evaluation of technology
compatibility and synergy based on OLX104C (Androgenic Alopecia) preclinical
studies. The companies will evaluate results achieved from this research
collaboration to explore the potential for further development and partnership.

Commenting on the announcement, Dong Ki Lee, CEO of OliX Pharmaceuticals said:
"We are very excited to collaborate with PCI Biotech. Combining our proprietary
asiRNA platform with PCI's leading fimaNAc delivery technology will
significantly accelerate our efforts to bring our dermatological RNAi programs
to the clinic. We also expect to expand the area of application to our cancer
immunotherapy pipeline and mRNA vaccines developed by our subsidiary, mCureX, in
the near future."

PCI Biotech's CEO, Per Walday, added: "We are very pleased to initiate this
exciting collaboration with OliX Pharmaceuticals. This collaboration builds on
the strong potential of our intracellular delivery platform technology for
nucleic acid based therapies, within a therapeutic field of good technological
fit. Combining the leading technologies of OliX Pharmaceuticals and PCI Biotech
may lead to new promising applications and we look forward to the
collaboration."

About OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical stage pharmaceutical company developing
therapeutics against a variety of disorders by down-regulating expression of
disease-causing genes, based on its own proprietary RNAi technology. The
Company's core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene
silencing technology based on RNA interference (RNAi), which is considered as
the most efficient gene silencing technology. Based on asiRNA technology, OliX
has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform
to effectively target locally administrable diseases, such as hypertrophic scar,
dry and wet age-related macular degeneration (AMD), subretinal fibrosis,
idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also
developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety
of liver diseases. For more information, please visit:
https://www.olixpharma.com

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialization of novel therapies for the
treatment of cancer through its innovative photochemical internalization (PCI)
technology platform, for intracellular delivery. PCI induces triggered endosomal
release that enables drugs to reach intracellular therapeutic targets.
Currently, PCI Bi

Da er vi snart i minus......er det mulig....

Ja litt flaut å se kursen dale? nå som det er så mye lovende.

Tenk å skrive så mange innlegg uten substans som det du og "sokrates" gjør. Flaut.

2 Gode nyheter på kort tid. 46 kommer først nå . At den fortsatt er på 20 tallet er jo lykke for de som vil inn nå.

HOLD PÅ AKSJENE SÅ BLIR DET RALLY!!

Ja meget lovende dette samarbeidet, ellers hadde ikke disse gått sammen.

Tampen brenner for et bra treff.

Du spår høye kurser raskt, Fast Finger :) Jeg håper jo du får rett :)

Hmm ....kan vere et godt treff dette.

hmm.... tror denne kan bli spennende fremover. Det var interne prioriteringer som gjorde at AZ ikke gikk videre, så kvaliteten på det de driver med er god. Nytt samarbeid lover godt.

Leveringsteknologien er tydeligvis interessant både for vanskelige kreftformer og genetisk betinget skallethet. Det viser bredden i muligheter dersom dette lykkes.

Går fort til 70kr igjen nå.

Svært interessante perspektiver og dessuten åpner for et bredere samarbeid

NÅ løper denne tilbake til 70 kr ...kjøøøøøp 🚀🚀🚀🚀🚀

Spennende og svært interessant samarbeid som åpner for innovasjon og medisinsk gjennombrudd